表紙:BRAFキナーゼ阻害剤の世界市場:薬剤別、適応症別、流通チャネル別、地域別-規模、シェア、展望、機会分析-2022~2028年
市場調査レポート
商品コード
1085723

BRAFキナーゼ阻害剤の世界市場:薬剤別、適応症別、流通チャネル別、地域別-規模、シェア、展望、機会分析-2022~2028年

BRAF Kinase Inhibitors Market, by Drug, by Indication, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 158 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.55円
BRAFキナーゼ阻害剤の世界市場:薬剤別、適応症別、流通チャネル別、地域別-規模、シェア、展望、機会分析-2022~2028年
出版日: 2022年05月21日
発行: Coherent Market Insights
ページ情報: 英文 158 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のBRAFキナーゼ阻害剤市場の主要企業は、特許の取得に注力しており、新興国のメーカーにとってより多くの機会を創出することが期待されます。しかし、市場における課題の一つは、患者の負担です。高コストであるため、患者は実際の治療体制からがん治療の代替手段にシフトしています。

当レポートでは、世界のBRAFキナーゼ阻害剤市場について調査分析し、市場の促進要因、抑制要因、市場機会、薬剤・適応症・流通チャネル・地域別市場分析、企業プロファイルに関する情報を提供しています。

目次

第1章 調査目的・前提条件

第2章 市場概要

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー
    • 市場内訳:薬剤別
    • 市場内訳:適応症別
    • 市場内訳:流通チャネル別
    • 市場内訳:地域別
  • コヒーレントオポチュニティマップ(COM)

第3章 市場力学、規制、および動向分析

  • 促進要因
  • 抑制要因
  • 市場機会
  • 影響分析
  • 製品発売
  • 主な発展
  • 規制シナリオ
  • PEST分析
  • 治療の進化
  • パイプライン分析
  • 償還シナリオ

第4章 BRAFキナーゼ阻害剤市場に対するCOVID-19の影響

  • 供給側と需要側の分析
  • 全体的な影響
  • 研究開発への影響

第5章 世界のBRAFキナーゼ阻害剤市場:薬剤別(2017~2028年(100万米ドル))

  • イントロダクション
  • ベムラフェニブ
  • ダブラフェニブ
  • リフィラフェニブ
  • エンコラフェニブ

第6章 世界のBRAFキナーゼ阻害剤市場:適応症別(2017~2028年(100万米ドル))

  • イントロダクション
  • 転移性黒色腫
  • 転移性肺がん
  • その他

第7章 世界のBRAFキナーゼ阻害剤市場:流通チャネル別(2017~2028年(100万米ドル))

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第8章 世界のBRAFキナーゼ阻害剤市場:地域別(2017~2028年(100万米ドル))

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東
  • アフリカ

第9章 競合情勢

  • 企業プロファイル
    • F. Hoffmann-La Roche AG
    • Novartis International AG
    • Pfizer, Inc.

第10章 セクション

目次
Product Code: CMI4240

BRAF is a kinase enzyme that helps control cell growth and signalling. It may be found in a mutated (changed) form in some types of cancer, including melanoma and colorectal cancer. Blocking mutated BRAF kinase proteins may help keep cancer cells from growing. Some BRAF kinase inhibitors are used to treat cancer. About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors. Two compounds (vemurafenib and dabrafenib) have achieved approval by the Food and Drug Administration (FDA) for the treatment of metastatic and unresectable BRAF-mutated melanomas.

Market Dynamics

Key players in the BRAF kinase inhibitors market are focusing on obtaining patents, which is expected to create more opportunities for BRAF kinase inhibitor drugs manufacturers in the emerging economies. For instance, in September 2016, Novartis International AG secured an Indian patent for its skin cancer (melanoma) drug Tafinlar, which is used for the treatment of metastatic melanoma, the most serious and life-threatening type of skin cancer that is associated with low survival rates.

However, one of the challenges in BRAF kinase inhibitors market is patient adherence. Due to the high cost of BRAF kinase inhibitor drugs, patients are shifting from the actual treatment regime to alternatives of cancer treatments. Alternative methods available for cancer treatments is expected to hinder growth of the BRAF kinase inhibitors market in the near future. For instance, metastatic cancer requires systemic therapy or medications given through mouth or injected into the bloodstream to reach cancer cells throughout the body such as chemotherapy or hormone therapy. Other treatments may include immunotherapy, radiation therapy, surgery or a combination of these.

Key features of the study:

  • This report provides in-depth analysis of the global BRAF kinase inhibitors market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global BRAF kinase inhibitors market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include F. Hoffmann-La Roche AG, Novartis International AG, and Pfizer, Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global BRAF kinase inhibitors market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for BRAF kinase inhibitors market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global BRAF Kinase Inhibitors Market, By Drug:
    • Vemurafenib
    • Dabrafenib
    • Lifirafenib
    • Encorafenib
  • Global BRAF Kinase Inhibitors Market, By Indication:
    • Metastatic Melanoma
    • Metastatic Lung Cancer
    • Others
  • Global BRAF Kinase Inhibitors Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global BRAF Kinase Inhibitors Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Drug:
    • Vemurafenib
    • Dabrafenib
    • Lifirafenib
    • Encorafenib
      • By Indication:
    • Metastatic Melanoma
    • Metastatic Lung Cancer
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Drug:
    • Vemurafenib
    • Dabrafenib
    • Lifirafenib
    • Encorafenib
      • By Indication:
    • Metastatic Melanoma
    • Metastatic Lung Cancer
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Drug:
    • Vemurafenib
    • Dabrafenib
    • Lifirafenib
    • Encorafenib
      • By Indication:
    • Metastatic Melanoma
    • Metastatic Lung Cancer
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Drug:
    • Vemurafenib
    • Dabrafenib
    • Lifirafenib
    • Encorafenib
      • By Indication:
    • Metastatic Melanoma
    • Metastatic Lung Cancer
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Drug:
    • Vemurafenib
    • Dabrafenib
    • Lifirafenib
    • Encorafenib
      • By Indication:
    • Metastatic Melanoma
    • Metastatic Lung Cancer
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
      • By Drug:
    • Vemurafenib
    • Dabrafenib
    • Lifirafenib
    • Encorafenib
      • By Indication:
    • Metastatic Melanoma
    • Metastatic Lung Cancer
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Company Profiles
    • F. Hoffmann-La Roche AG*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Novartis International AG
    • Pfizer, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug
    • Market Snippet, By Indication
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Drivers
  • Restraints
  • Market Opportunities
  • Impact Analysis
  • Product Launches
  • Key Developments
  • Regulatory Scenario
  • PEST Analysis
  • Treatment Evolution
  • Pipeline Analysis
  • Reimbursement Scenario

4. Impact of COVID-19 on BRAF Kinase Inhibitors Market

  • Supply Side And Demand Side Analysis
  • Overall Impact
  • Impact on Research and Development

5. Global BRAF Kinase Inhibitors Market, By Drug, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Vemurafenib
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Dabrafenib
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Lifirafenib
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Encorafenib
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global BRAF Kinase Inhibitors Market, By Indication, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Metastatic Melanoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Metastatic Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global BRAF Kinase Inhibitors Market, By Distribution Channel, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

8. Global BRAF Kinase Inhibitors Market, By Region, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2028
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East
    • Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

  • Company Profiles
    • F. Hoffmann-La Roche AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact